MRI Molecular Imaging Agents - from fundamental design to In Vivo Applications

MRI 分子成像剂 - 从基础设计到体内应用

• 批准号: DP110104299
• 负责人: Prof Andrew Whittaker
• 金额: $ 61.39万
• 依托单位: The University of Queensland
• 依托单位国家: 澳大利亚
• 项目类别: Discovery Projects
• 财政年份: 2011
• 资助国家: 澳大利亚
• 起止时间: 2011-01-01 至 2015-12-31
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/DP110104299
• 关键词: MRI; Molecular; Imaging; Agents; fundamental

Of approximately 60 million magnetic resonance imaging (MRI) procedures performed annually worldwide, around 30 per cent of these use MRI imaging agents. Imaging agents allow the doctors to study blood flow and to identify particular tissue types and diseases. This project will lead to new classes of high-performance imaging agents which offer the prospect of faster more accurate diagnosis.

在全世界每年进行的约6 000万次磁共振成像（MRI）手术中，约30%使用MRI成像剂。成像剂使医生能够研究血流并识别特定的组织类型和疾病。该项目将导致新型高性能成像剂的出现，从而为更快更准确的诊断提供前景。